Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Introduction new ppt!


Published on

This presentation is related to research sector carried out by me regarding drug synthessis

  • Be the first to comment

Introduction new ppt!

  1. 1. Synthesis of (±) - Linezolid Abhijeet Patil. M.Sc. Chemistry. Fergusson College, Pune.
  2. 2. INTRODUCTION <ul><li>Antibiotic – kills or inhibits growth of bacteria </li></ul><ul><li>Important for improving life expectancy of human population </li></ul><ul><li>To overcome drug resistance it is necessary to discover a new series of antibiotic classes </li></ul><ul><li>Hence, oxazolidinone (Linezolid) brought in clinical use </li></ul><ul><li>It has unique mode of action- inhibition of bacterial protein synthesis at early stage </li></ul><ul><li>Failure of penicillin and methicillin led to the invention of Linezolid </li></ul>
  3. 3. Clinical Applications of Linezolid <ul><li>Skin infections </li></ul><ul><li>Nosocomial pneumonia </li></ul><ul><li>Liver diseases </li></ul><ul><li>Cure of Tuberculosis </li></ul>
  4. 4. Synthesis of (±) – Linezolid: Scheme
  5. 5. Synthesis: 3-Fluoro-4-morpholinylnitrobenzene
  6. 6. Synthesis: 3-Fluoro-4-morpholinylaniline
  7. 7. Synthesis: N-Carboethoxy-3-fluoro-4-morpholinylaniline
  8. 8. Synthesis: Ethyl N-allyl N-(3-fluoro-4-morpholinophenyl) carbamate
  9. 9. Synthesis: 5-(Iodomethyl)-3-(4-morpholinophenyl) oxazolidin-2-one The obtained iodolactone was unstable.
  10. 10. Synthesis: [N-3-(3-Fluoro-4-morphylinyl phenyl)-2-oxo-5-oxazolidinyl] methyl azide
  11. 11. Synthesis: (±) - LINEZOLID
  12. 12. CONCLUSION <ul><li>(±) – LINEZOLID was synthesized in 7 steps. </li></ul><ul><li>The intermediates obtained at each step was isolated, purified by </li></ul><ul><li>chromatographic techniques like Thin layer chromatography and Column </li></ul><ul><li>chromatography. </li></ul><ul><li>These intermediates were characterized by FT-IR, NMR ( 1 H) spectroscopy. </li></ul><ul><li>The purpose of undertaking this project was to get an experience in multi- </li></ul><ul><li>step organic synthesis using sophisticated techniques at N.C.L. </li></ul>
  13. 13. REFERENCES <ul><li>S.J. Brickner, D.K. Hutchinson, M.R. Barbachyn, P.R. Mannien, D.A. Ulanowicz, S.A. Garmon, K.C. Grega, D.S. Tropps, C.W. Ford and G.E. Zurenks, . J. Med. Chem . 1996 , 39 , 673-679. </li></ul><ul><li>Swartz, M.N. Hospital acquired Infections: Diseases with Increasingly Limited Therapies. Proc. Natl. Sci .U .S.A 1994, 91 , 2420-2427. </li></ul><ul><li>Boyce. J. M, Opal, S. M, Chow, J. W, Zervos. M. J, Potter-Bynos. G, Sherman C. B, Romulo. R. L, C Fortna. S; J. Clin. Microbiolol. 1994, 1148-1153. </li></ul><ul><li>Gregory. W. A, Britteli. D. R, Wang. C. L. ; Wuonola. M. A.; McRipley. R.J; Eustice, D. C; Bartholomew, P. T, Slee. A. M. Forbes, M; J. Med. Chem. 1989, 32, 1673-1681. </li></ul><ul><li>Wang, C. L. J. Gregory, W. A.; Wuonola; Tetrahedron. 1989, 1323-1326. </li></ul><ul><li>Iwakura, Y.; Izawa, S. I; J. Org. Chem. 1964, 29, 379. </li></ul>
  14. 14. <ul><li>Herweh, J.E.; Kauffmann, W. J; Tetrahedron. Lett. 1971, 809-812 </li></ul><ul><li>Blumberg, H. M.; Rimland, P; Carroll, D. J.; Terry, P.; Wachsmuth, I. K. </li></ul><ul><li>J. Infec. Dis, 1991, 163, 1279-1285. </li></ul><ul><li>Fugitt, R. B.; Luckenbaugh, R W. U.S. Patent No.4128654, Dec. 5, 1978. </li></ul><ul><li>Gregory, W. A; U.S. Patent No.4461773, July 24, 1984. </li></ul><ul><li>Gregory, W. A; U. S. Patent No. 4,705,799, Nov 10, 1987 </li></ul>
  15. 15. THANK YOU <ul><li>Dr. J. M. Gajbhiye. </li></ul><ul><li>Pankaj Mahajan. </li></ul><ul><li>Parimal Naik. </li></ul><ul><li>Dr.M.N.Deshmukh . </li></ul>